139 related articles for article (PubMed ID: 33826473)
1. Outcomes of Repository Corticotropin Gel for Ocular Sarcoidosis.
Oh DJ; Singh A; Kanu LN; Lobo-Chan AM; MacIntosh PW; Bhat P
Ocul Immunol Inflamm; 2022 Aug; 30(6):1420-1424. PubMed ID: 33826473
[TBL] [Abstract][Full Text] [Related]
2. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
[TBL] [Abstract][Full Text] [Related]
4. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
[TBL] [Abstract][Full Text] [Related]
5. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
6. Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study.
Nguyen QD; Anesi SD; Chexal S; Chu DS; Dayani PN; Leng T; Meleth AD; Sallam AA; Sheppard JD; Silverstein SM; Toyos M; Wang RC; Foster CS
Acta Ophthalmol; 2021 Sep; 99(6):669-678. PubMed ID: 33751822
[TBL] [Abstract][Full Text] [Related]
7. Change in visual acuity and retinal structures following Repository Corticotropin Injection (RCI) therapy in patients with acute demyelinating optic neuritis: Improvement in low contrast visual acuity in both affected and contralateral eyes in a single-armed open-label study.
Scannell Bryan M; Sergott RC
J Neurol Sci; 2019 Dec; 407():116505. PubMed ID: 31706456
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis.
Bennett JL; Grove NC; Johnson RK; Mizenko C; DuPont JC; Wagner BD; Lynch AM; Frohman TC; Shindler KS; Frohman EM
J Neuroophthalmol; 2023 Sep; 43(3):323-329. PubMed ID: 37261907
[TBL] [Abstract][Full Text] [Related]
9. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
11. Repository Corticotropin Injection as an Alternative Treatment for Refractory Ocular Mucous Membrane Pemphigoid.
Sharon Y; Anesi SD; Martinez CE; Huang AJW; Foster CS; Chu DS
Cornea; 2022 Jan; 41(1):45-51. PubMed ID: 34050065
[TBL] [Abstract][Full Text] [Related]
12. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.
Mirsaeidi M; Baughman RP
Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366
[TBL] [Abstract][Full Text] [Related]
13. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ
J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249
[No Abstract] [Full Text] [Related]
14. Publication bias, Open-Labeled Trials and Sky Rocketing Costs- Past, Present and Future of Repository Corticotropin Injection?
Lobo-Chan AM; MacIntosh P; Bhat P
Ocul Immunol Inflamm; 2022 Aug; 30(6):1505-1507. PubMed ID: 34242098
[TBL] [Abstract][Full Text] [Related]
15. Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements.
Dammacco R; Biswas J; Kivelä TT; Zito FA; Leone P; Mavilio A; Sisto D; Alessio G; Dammacco F
Int Ophthalmol; 2020 Dec; 40(12):3453-3467. PubMed ID: 32740881
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestations and risk factors for poor visual outcomes of ocular sarcoidosis in Taiwan.
Lai IW; Lin CP; Hsieh YT; Yeh PT
J Formos Med Assoc; 2022 Aug; 121(8):1560-1566. PubMed ID: 35027256
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.
Bhat P; Cervantes-Castañeda RA; Doctor PP; Anzaar F; Foster CS
Ocul Immunol Inflamm; 2009; 17(3):185-90. PubMed ID: 19585361
[TBL] [Abstract][Full Text] [Related]
18. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
Wan GJ; Niewoehner J; Hayes K
Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
[TBL] [Abstract][Full Text] [Related]
19. [Ocular Manifestations in Sarcoidosis].
Walscheid K; Tappeiner C; Heiligenhaus A
Klin Monbl Augenheilkd; 2016 May; 233(5):594-600. PubMed ID: 27187879
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis.
Bert A; El Jammal T; Kodjikian L; Gerfaud-Valentin M; Jamilloux Y; Seve P
Ocul Immunol Inflamm; 2024 Feb; 32(2):154-160. PubMed ID: 36749910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
